—Brensocatib Reduced Risk of Exacerbations Irrespective of Disease Severity in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE) in Phase 2 WILLOW Subgroup Analysis—
Read more at prnewswire.comInsmed Presents Range of New Study Findings at American Thoracic Society 2023 International Conference
Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.